You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
|
|---|---|
| Published in |
Journal of Hematology & Oncology, November 2015
|
| DOI | 10.1186/s13045-015-0224-3 |
| Pubmed ID | |
| Authors |
Shundong Cang, Chaitanya Iragavarapu, John Savooji, Yongping Song, Delong Liu |
| Abstract |
With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 318 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| India | 1 | <1% |
| Unknown | 316 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 70 | 22% |
| Student > Master | 45 | 14% |
| Researcher | 39 | 12% |
| Student > Bachelor | 37 | 12% |
| Student > Doctoral Student | 18 | 6% |
| Other | 39 | 12% |
| Unknown | 70 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 86 | 27% |
| Agricultural and Biological Sciences | 40 | 13% |
| Medicine and Dentistry | 38 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 8% |
| Chemistry | 20 | 6% |
| Other | 32 | 10% |
| Unknown | 78 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#996,537
of 23,213,531 outputs
Outputs from Journal of Hematology & Oncology
#43
of 1,204 outputs
Outputs of similar age
#18,128
of 388,410 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 23 outputs
Altmetric has tracked 23,213,531 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,204 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,410 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.